Posted by Michael Wonder on 07 Nov 2025
Gilead's Vemlidy now reimbursed as initial therapy for chronic hepatitis B in Korea
5 November 2025 - Gilead Sciences Korea announced that, starting this month, Vemlidy (tenofovir alafenamide hemifumarate) will be covered under expanded National Health Insurance for chronic hepatitis B treatment, enabling broader patient access.
The coverage expansion follows the Ministry of Health and Welfare's revised notice on medical benefit application standards.
